Lactoferrin and Nanotechnology: The Potential for Cancer Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 May 27

PMID 37242604

Authors

Tuan Hiep Tran

Phuong Thi Thu Tran

Duy Hieu Truong

Affiliations

Soon will be listed here.

Abstract

Lactoferrin (Lf)-a glycoprotein of the transferrin family-has been investigated as a promising molecule with diverse applications, including infection inhibition, anti-inflammation, antioxidant properties and immune modulation. Along with that, Lf was found to inhibit the growth of cancerous tumors. Owing to unique properties such as iron-binding and positive charge, Lf could interrupt the cancer cell membrane or influence the apoptosis pathway. In addition, being a common mammalian excretion, Lf offers is promising in terms of targeting delivery or the diagnosis of cancer. Recently, nanotechnology significantly enhanced the therapeutic index of natural glycoproteins such as Lf. Therefore, in the context of this review, the understanding of Lf is summarized and followed by different strategies of nano-preparation, including inorganic nanoparticles, lipid-based nanoparticles and polymer-based nanoparticles in cancer management. At the end of the study, the potential future applications are discussed to pave the way for translating Lf into actual usage.

Citing Articles

Lactoferrin as a Versatile Agent in Nanoparticle Applications: From Therapeutics to Agriculture.

Akdasci E, Eker F, Duman H, Singh P, Bechelany M, Karav S Nanomaterials (Basel). 2024; 14(24.

PMID: 39728554 PMC: 11728633. DOI: 10.3390/nano14242018.

Structural and in vitro anticancer properties of the kaempferol-lactoferrin complex.

Xue P, Zhao H, You X, Yue W Food Sci Nutr. 2024; 12(11):9046-9055.

PMID: 39620007 PMC: 11606874. DOI: 10.1002/fsn3.4479.

References

Rosenholm J, Sahlgren C, Linden M . Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges. Nanoscale. 2010; 2(10):1870-83. DOI: 10.1039/c0nr00156b. View

Miranda-Goncalves V, Lameirinhas A, Henrique R, Jeronimo C . Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Front Genet. 2018; 9:427. PMC: 6190739. DOI: 10.3389/fgene.2018.00427. View

Marshall L, Oguejiofor W, Price R, Shur J . Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin. Int J Pharm. 2016; 514(2):399-406. DOI: 10.1016/j.ijpharm.2016.09.034. View

Qi N, Duan W, Gao D, Ma N, Zhang J, Feng J . "Guide" of muscone modification enhanced brain-targeting efficacy and anti-glioma effect of lactoferrin modified DTX liposomes. Bioeng Transl Med. 2023; 8(2):e10393. PMC: 10013770. DOI: 10.1002/btm2.10393. View

Lv Z, Jin L, Gao W, Cao Y, Zhang H, Xue D . Novel YOF-Based Theranostic Agents with a Cascade Effect for NIR-II Fluorescence Imaging and Synergistic Starvation/Photodynamic Therapy of Orthotopic Gliomas. ACS Appl Mater Interfaces. 2022; 14(27):30523-30532. DOI: 10.1021/acsami.2c05354. View

Jena L, McErlean E, McCarthy H . Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res. 2019; 10(2):304-318. PMC: 7066289. DOI: 10.1007/s13346-019-00679-2. View

Bick R, Frenkel E . Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost. 2000; 5 Suppl 1:S7-15. DOI: 10.1177/10760296990050s103. View

Zhang Z, Yang J, Min Q, Ling C, Maiti D, Xu J . Holo-Lactoferrin Modified Liposome for Relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer. Small. 2019; 15(6):e1803703. DOI: 10.1002/smll.201803703. View

Abu-Serie M, El-Fakharany E . Efficiency of novel nanocombinations of bovine milk proteins (lactoperoxidase and lactoferrin) for combating different human cancer cell lines. Sci Rep. 2017; 7(1):16769. PMC: 5711920. DOI: 10.1038/s41598-017-16962-6. View

10.

Su Y, Fang J, Liao C, Lin C, Li Y, Hu S . Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy. Theranostics. 2015; 5(11):1233-48. PMC: 4568451. DOI: 10.7150/thno.12843. View

11.

Chen H, Tang L, Qin Y, Yin Y, Tang J, Tang W . Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur J Pharm Sci. 2010; 40(2):94-102. DOI: 10.1016/j.ejps.2010.03.007. View

12.

Pandey V, Gajbhiye K, Soni V . Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Drug Deliv. 2014; 22(2):199-205. DOI: 10.3109/10717544.2013.877100. View

13.

Shubayev V, Pisanic 2nd T, Jin S . Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev. 2009; 61(6):467-77. PMC: 2700776. DOI: 10.1016/j.addr.2009.03.007. View

14.

Sakai T, Banno Y, Kato Y, Nozawa Y, Kawaguchi M . Pepsin-digested bovine lactoferrin induces apoptotic cell death with JNK/SAPK activation in oral cancer cells. J Pharmacol Sci. 2005; 98(1):41-8. DOI: 10.1254/jphs.fpj04047x. View

15.

Otto C, Schmidt S, Kastner C, Denk S, Kettler J, Muller N . Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells. Neoplasia. 2019; 21(11):1110-1120. PMC: 6888720. DOI: 10.1016/j.neo.2019.10.003. View

16.

Chisolm D, Weinmann A . Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation. Annu Rev Immunol. 2018; 36:221-246. DOI: 10.1146/annurev-immunol-042617-053127. View

17.

Altwaijry N, Somani S, Parkinson J, Tate R, Keating P, Warzecha M . Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Deliv. 2018; 25(1):679-689. PMC: 6058574. DOI: 10.1080/10717544.2018.1440666. View

18.

Pang Z, Feng L, Hua R, Chen J, Gao H, Pan S . Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol Pharm. 2010; 7(6):1995-2005. DOI: 10.1021/mp100277h. View

19.

Kondapi A . Targeting cancer with lactoferrin nanoparticles: recent advances. Nanomedicine (Lond). 2020; 15(21):2071-2083. DOI: 10.2217/nnm-2020-0090. View

20.

Yin S, Efferth T, Jian F, Chen Y, Liu C, Wang A . Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1. Oncotarget. 2016; 7(28):43629-43653. PMC: 5190049. DOI: 10.18632/oncotarget.9660. View